Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types

Background The inflamed immune phenotype (IIP), defined by enrichment of tumor-infiltrating lymphocytes (TILs) within intratumoral areas, is a promising tumor-agnostic biomarker of response to immune checkpoint inhibitor (ICI) therapy. However, it is challenging to define the IIP in an objective and...

Full description

Saved in:
Bibliographic Details
Main Authors: Jeanne Shen, Sergio Pereira, Chan-Young Ock, Yung-Jue Bang, Seulki Kim, Sehhoon Park, Se-Hoon Lee, George A Fisher, Young Kwang Chae, Yoon-La Choi, Jin-Haeng Chung, Tony S K Mok, Leeseul Kim, Jun-Eul Hwang, Gahee Park, Sanghoon Song, Seunghwan Shin, Yoojoo Lim, Wonkyung Jung, Heon Song, Hyojin Kim, Taebum Lee, Sukjun Kim, Chang Ho Ahn, Seokhwi Kim, Ben W Dulken, Stephanie Bogdan, Maggie Huang, Chiyoon Oum, Siraj M. Ali
Format: Article
Language:English
Published: BMJ Publishing Group 2024-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/2/e008339.full
Tags: Add Tag
No Tags, Be the first to tag this record!